MRK Gets EU Approval
MRK's KEYTRUDA and Padcev approved by European Commission for treatment of muscle-invasive bladder cancer
MRK European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer